NMD Pharma receives Orphan Drug Designation from FDA for NMD670 for the Treatment of Myasthenia Gravis
September 27, 2022 07:00 ET
|
NMD Pharma
FDA grants Orphan Drug Designation for NMD670 for the Treatment of Myasthenia Gravis Aarhus, Denmark, 27 September 2022 – NMD Pharma A/S, a clinical stage biotech company developing first-in-class...
NMD Pharma appoints Dr. Jorge A. Quiroz as EVP, Chief Medical Officer
May 10, 2022 07:00 ET
|
NMD Pharma
PRESS RELEASE NMD Pharma appoints Dr. Jorge A. Quiroz as EVP, Chief Medical Officer Dr. Quiroz brings extensive US and European clinical and regulatory expertiseRole will be based in Boston,...
NMD Pharma expands its US presence
May 03, 2022 07:00 ET
|
NMD Pharma
PRESS RELEASE NMD Pharma expands its US presence Creates US subsidiary and increases US R&D and staff recruitment activity Aarhus, Denmark, 3 May 2022 – NMD Pharma A/S, a clinical stage biotech...
NMD Pharma Raises €35 Million in a new Financing
February 15, 2022 07:00 ET
|
NMD Pharma
NMD Pharma Raises €35 Million in a new Financing - New investor Jeito Capital joins current NMD Pharma investors - Proceeds will be used to progress lead clinical programs, expand the number of...
NMD Pharma Raises €35 Million in a new Financing
February 15, 2022 01:00 ET
|
NMD Pharma
NMD Pharma Raises €35 Million in a new Financing - New investor Jeito Capital joins current NMD Pharma investors - Proceeds will be used to progress lead clinical programs, expand the number of...
NMD Pharma Initiates ESTABLISH Study in Patients with Charcot-Marie-Tooth Disease
July 08, 2021 07:00 ET
|
NMD Pharma
PRESS RELEASE NMD Pharma Initiates ESTABLISH Study in Patients with Charcot-Marie-Tooth Disease The international observational study will be conducted in collaboration with Aarhus University and...
NMD Pharma Initiates ESTABLISH Study in Patients with Charcot-Marie-Tooth Disease
July 08, 2021 02:00 ET
|
NMD Pharma
PRESS RELEASE NMD Pharma Initiates ESTABLISH Study in Patients with Charcot-Marie-Tooth Disease The international observational study will be conducted in collaboration with Aarhus University and...
NMD Pharma Doses the First Myasthenia Gravis Patient in a Combined Phase I/IIa Clinical Trial of NMD670
June 30, 2021 07:00 ET
|
NMD Pharma
NMD Pharma Doses the First Myasthenia Gravis Patient in a Combined Phase I/IIa Clinical Trial of NMD670 Aarhus, Denmark, 30 June 2021 – NMD Pharma A/S, a biotech company leading in the development...
NMD Pharma Doses the First Myasthenia Gravis Patient in a Combined Phase I/IIa Clinical Trial of NMD670
June 30, 2021 02:00 ET
|
NMD Pharma
NMD Pharma Doses the First Myasthenia Gravis Patient in a Combined Phase I/IIa Clinical Trial of NMD670 Aarhus, Denmark, 30 June 2021 – NMD Pharma A/S, a biotech company leading in the development...
NMD Pharma Initiates an Observational Pilot Study Investigating the Effects of Sarcopenia on Neuromuscular Transmission in Older Adults
June 01, 2021 07:00 ET
|
NMD Pharma
PRESS RELEASE NMD Pharma Initiates an Observational Pilot Study Investigating the Effects of Sarcopenia on Neuromuscular Transmission in Older Adults Aarhus, Denmark, 1 June 2021 – NMD Pharma A/S,...